|
G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - G1 Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - G1 Therapeutics; G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
Travel, Accommodations, Expenses - G1 Therapeutics |
|
|
Employment - G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
Patents, Royalties, Other Intellectual Property - Patents held by G1 Therapeutics (Inst) |
|
|
Employment - G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
Patents, Royalties, Other Intellectual Property - Patents involve with G1 therapeutics (Inst) |
|
|
Employment - G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
|
|
Employment - G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
|
|
Stock and Other Ownership Interests - ICON Clinical Research |
|
|
Employment - G1 Therapeutics |
Leadership - G1 Therapeutics |
Stock and Other Ownership Interests - G1 Therapeutics |
|
|
Employment - Epizyme (I); G1 Therapeutics |
Stock and Other Ownership Interests - Amarin Corporation; Epizyme (I); G1 Therapeutics |